Telehealth Weight Loss/GLP-1 Prescribing: What Prescribers Can Do in North Carolina

You’re a psychiatrist or PMHNP seeing patients struggle with obesity—often worsened by the very medications you prescribe. Maybe you’ve watched patients gain 30+ pounds on olanzapine, or heard a patient ask if you can prescribe ‘Ozempic’ alongside their antidepressant. The question isn’t academic anymore: Should you be prescribing weight loss medications as part of psychiatric care?

Short answer: Yes, with the right training and approach. Here’s what you actually need to know about scope of practice, state regulations, and building this into your telehealth practice.

The Clinical Case: Why Psychiatrists Are Entering Weight Management

The overlap is undeniable. Many psychiatric medications cause significant weight gain—antipsychotics, mood stabilizers, even some antidepressants. Your patients deal with:

• Medication-induced metabolic syndrome (20-30 lb weight gain on antipsychotics isn’t rare)
• Obesity complicating mental health (depression worsens with weight gain, creating a vicious cycle)
• Fragmented care (bouncing between psychiatry, endocrinology, and primary care with no one coordinating)

GLP-1 receptor agonists (semaglutide/Wegovy, tirzepatide, liraglutide) have changed the game. Originally diabetes drugs, they’re now FDA-approved for obesity and showing ancillary benefits psychiatrists care about:

• Reduced cravings in substance use disorders
• Improved mood scores independent of weight loss in clinical trials
• Lower inflammation that may benefit depression neurobiology

Dr. Elliott Lewis, a psychiatrist board-certified in obesity medicine, puts it plainly: ‘If we truly understand that metabolic and mental health systems are inseparable, then psychiatrists being involved in metabolic treatment makes complete sense.’ You’re already monitoring glucose and lipids for patients on psych meds—prescribing a GLP-1 to address weight isn’t a leap, it’s integrated care.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Scope of Practice: Are You Legally Allowed to Prescribe Weight Loss Meds?

Psychiatrists (MD/DO): You Have Full Authority

As a physician, you can prescribe any FDA-approved medication in all 50 states—obesity drugs, GLP-1s, phentermine (Schedule IV), whatever fits your clinical judgment. There’s no separate certification required to write for weight management.

The real question is competency, not permission. State medical boards expect you to practice within your training. If you’re prescribing Wegovy, you should:

• Understand GLP-1 pharmacology (onset, titration, side effects like nausea and pancreatitis risk)
• Know obesity treatment standards (BMI criteria, ruling out secondary causes like hypothyroidism)
• Monitor appropriately (weight, vitals, labs, mental health status)

Many psychiatrists pursue obesity medicine board certification (ABOM) to solidify their expertise. It’s ~60 hours of CME plus an exam, and it’s open to any specialty. This directly addresses the ‘is this your lane?’ question—you’re now formally trained in metabolic care, not just dabbling.

One psychiatrist wrote: ‘It’s not outside my scope of practice…it’s part of comprehensive treatment when done competently. I manage medications that affect both metabolic and mental health systems.’ With training, you’re well-positioned—arguably better than some PCPs who don’t understand the psychiatric medication interactions.

PMHNPs: State-by-State Patchwork

Nurse practitioners face a wildly inconsistent landscape. Whether you can prescribe weight loss meds independently depends entirely on your state’s scope laws:

Full Practice Authority States (~25 states + DC): You can prescribe autonomously, including GLP-1s and even controlled substances like phentermine (within your competency). Examples: Washington, Oregon, New Mexico, Arizona, Colorado, Montana, Iowa, Minnesota, Wisconsin, Maryland, Connecticut, Rhode Island, New Hampshire, Vermont, Maine, Alaska, Hawaii, DC.

Reduced/Restricted Practice States (~25 states): You need a collaborating or supervising physician to prescribe. The physician doesn’t need to co-sign every script, but you must have a written agreement on file and meet state-specific oversight requirements.

Reality check: Even in ‘independent’ states, insurance companies and pharmacies sometimes balk at NP-signed prescriptions for expensive drugs like Wegovy without a physician’s involvement. It’s not a legal requirement, but it’s a practical headache. Some telehealth platforms have MDs oversee all GLP-1 prescribing just to smooth billing and prior auths.

Specialty scope consideration: You’re a psychiatric NP. Your formal training emphasized mental health, not endocrinology or obesity medicine. Can you prescribe weight loss meds? Legally, most states define scope broadly as ‘what you’re competent to do,’ not rigidly by diagnosis. If you’re managing a patient’s medication-induced weight gain as part of psychiatric treatment, that’s defensible. If you’re opening a weight loss clinic for the general public with no psych component, expect scrutiny.

Practical approach for PMHNPs:

• If your state requires collaboration, ensure your agreement explicitly covers weight management prescribing (including controlled substances if using phentermine)
• Pursue additional training (obesity CME, certification if ambitious) to demonstrate competency
• Document clearly: ‘Patient has gained 35 lbs on quetiapine, BMI now 33, significant distress impacting depression recovery. Initiating semaglutide 0.25mg weekly as part of comprehensive psychiatric care plan.’
• Consider limiting to patients already under your psychiatric care rather than pure weight-loss-only patients, at least initially

State-Specific Rules You Can’t Ignore

Federal law (DEA, FDA) sets a baseline, but states add layers that can catch you off guard. Here are the priority states for Klarity’s provider base:

Florida: Strict Rules, Heavy Enforcement

Florida’s Board of Medicine has explicit obesity prescribing regulations (Rule 64B15-14.004) that apply to MDs, DOs, and any delegated prescribers (NPs/PAs):

• BMI criteria: Patient must have BMI ≥30, or ≥27 with comorbidity, to qualify for anti-obesity meds
• Comprehensive exam required before prescribing (can be done via telehealth if thorough—history, physical assessment, labs to rule out thyroid/endocrine causes)
• Written informed consent documenting risks/benefits
• Follow-up every 3 months minimum for anyone on weight loss medication (telehealth visits count)
• ‘Weight-Loss Consumer Bill of Rights’ must be given to patient at start

Controlled substance telehealth ban: Florida prohibits prescribing controlled substances via telehealth except for psychiatric treatment, inpatient/hospice, or acute pain. This creates a gray area: phentermine (Schedule IV appetite suppressant) can’t be prescribed via telehealth for pure weight loss. However, if you’re a psychiatrist treating a psychiatric condition and prescribing phentermine as part of that treatment, you may fall under the ‘psychiatric disorder’ exemption—but this hasn’t been tested in enforcement. Safer bet: Use non-controlled GLP-1s (Wegovy, Saxenda) via telehealth in Florida, or arrange an in-person exam for phentermine.

NP collaboration: Florida requires all APRNs to have a physician protocol unless they’re an ‘autonomous APRN’ (only available to primary care specialties, not psych NPs, and still can’t prescribe controlled substances independently). Bottom line: PMHNPs in Florida need an MD collaborator to prescribe any weight loss meds.

Texas: Physician Oversight Mandatory

Texas is a strict delegation state. No NP independence:

• All NPs must have a Prescriptive Authority Agreement with a Texas-licensed physician
• Agreement must specify what the NP can prescribe (including weight meds) and require monthly MD-NP chart reviews
• One physician can supervise max 7 NP/PAs in most settings

Prescribing rules: Texas doesn’t have obesity-specific regulations like Florida, but standard medical practice applies. You can’t prescribe Schedule II stimulants (amphetamines) for weight loss, but phentermine (IV) and GLP-1s are fine.

Telehealth: Texas allows it; no extra controlled substance ban for telehealth. Must check the state Prescription Drug Monitoring Program for controlled Rx.

Corporate practice of medicine: Only physicians can own medical practices. Telehealth companies use MSO structures with physician medical directors to comply.

California: Transitioning to NP Independence (Slowly)

NP scope: California’s AB 890 is phasing in full practice authority for NPs:

• After 3 years/4,600 supervised hours, NPs can practice without physician oversight
• Full independent practice (opening own clinics) starts January 1, 2026 for certified NPs

Current state (2026): Many experienced NPs now have independence, but still can’t independently prescribe controlled substances until they complete the transition period. California’s Board of Nursing still considers the state ‘restricted practice’ during the transition.

CPOM: California’s Corporate Practice of Medicine doctrine is strict—only MDs/DOs can own medical clinics. NPs with independence still need to work within physician-owned entities or MSOs for regulatory compliance.

Prescribing: No California-specific obesity drug rules. Standard of care applies (document BMI, informed consent, monitoring plan).

New York: Experienced NPs Can Go Solo

NP scope: After 3,600 hours (about 2 years), NPs can practice independently without a collaborating physician (NP Modernization Act). Many experienced PMHNPs in NY work autonomously.

Prescribing: No state-specific obesity treatment regulations. Must check the state Prescription Monitoring Program (I-STOP) before prescribing any Schedule II-IV controlled substance (including phentermine).

Telehealth: NY is very telehealth-friendly. Payment parity law requires insurers to reimburse telehealth visits equally to in-person (effective 2022). No state ban on controlled substance prescribing via telehealth—follows federal rules.

Pennsylvania: Collaboration Still Required

NP scope: All NPs need a collaborative agreement with a physician to prescribe. No full practice authority yet (legislation keeps stalling).

• Agreement must list drug categories NP can prescribe
• Physician doesn’t need to be on-site but must be available for consult
• One physician can collaborate with up to 4 NPs

Prescribing: No special obesity rules beyond standard practice. If prescribing controlled substances, the collaboration agreement should specify physician notification/consultation for new CS indications.

Telehealth: PA allows it; no extra restrictions on controlled substance prescribing beyond federal law. Medicaid reimburses telehealth at parity; commercial insurance parity isn’t fully mandated yet but many plans comply.

Illinois: Best State for PMHNP Independence

NP scope: Illinois allows Full Practice Authority for experienced APRNs:

• Requires ≥4,000 hours clinical experience + ≥250 hours continuing education
• FPA APRNs can prescribe independently, including controlled substances

For PMHNPs with FPA, you can prescribe weight loss meds autonomously. If you don’t have FPA yet, you need a collaborative agreement.

Reimbursement win: Illinois Medicaid pays APRNs at 100% of physician rates (not the typical 85%). This is huge for NP income.

Prescribing: No state obesity-specific rules. Must have a separate Illinois Controlled Substance license to prescribe any CS.

Telehealth: Strong parity laws. State-regulated plans must cover and pay telehealth equally to in-person.

The Psychiatric Safety Question: Do GLP-1s Cause Suicidal Ideation?

You’ve seen the headlines. Reports of suicidal thoughts on Ozempic made waves. Here’s what the evidence actually shows:

Meta-analysis in JAMA Psychiatry (2025): No increase in depression or suicidality with GLP-1 medications vs. placebo across multiple large trials. The forest plot was reassuring—no signal of harm.

FDA and EMA reviews: Both agencies found no causal link between GLP-1s and suicidal behavior after analyzing post-market data.

STEP trials (semaglutide for obesity): Participants actually showed slightly lower rates of depressive symptoms compared to placebo.

Clinical bottom line: With proper monitoring, GLP-1s don’t destabilize mental health. Some patients report improved mood (possibly from weight loss, reduced inflammation, or direct CNS effects we don’t fully understand yet). Standard practice: screen for suicidal ideation at each visit (you’re already doing this), and document any mood changes. No different from monitoring a new antidepressant.

One psychiatrist who prescribes GLP-1s said: ‘I’ve seen meaningful results with minimal psychiatric side effects. The bigger concern is nausea and GI issues, not mood.’

Telehealth Prescribing: Navigating Federal vs. State Rules

Federal Waivers (Still Active Through 2025)

The DEA’s COVID-era telehealth flexibilities have been extended multiple times. As of late 2025, the Fourth Extension runs through December 31, 2025, allowing providers to prescribe controlled substances (including phentermine) via telehealth without a prior in-person exam.

Catch: This is federal permission. State law can override it.

States That Ban or Restrict Telehealth Controlled Substance Prescribing

Despite federal green lights, about 8-10 states still prohibit or heavily restrict it:

Florida: Cannot prescribe controlled substances via telehealth for weight loss (exception: psychiatric treatment—see gray area above)

Alabama: Requires in-person exam before prescribing any controlled substance via telehealth

Idaho, South Carolina, New Jersey: Similar in-person requirements or telehealth bans for controlled drugs in certain contexts

Practical solution: If you’re prescribing in a ‘red’ state:

• Use non-controlled GLP-1s (Wegovy, Saxenda, tirzepatide)—no state restrictions
• If patient needs phentermine, arrange a one-time in-person exam (or hybrid model: local provider does physical, you manage ongoing care via telehealth)
• Document thoroughly: even if legal, sloppy telehealth prescribing (5-minute consult, no follow-up) can trigger board investigations

Best Practices for Telehealth Weight Management

State boards expect the same standard of care whether you’re in-person or remote:

Initial visit (video required):

• Full history: weight trajectory, previous weight loss attempts, diet/exercise habits, medications (especially yours that caused gain)
• Screen for contraindications: pregnancy, history of pancreatitis, MEN2 syndrome, severe GI disorders
• Assess mental health: eating disorders, depression, motivation and readiness for treatment
• Review vitals: ask patient to share recent BP, weight (some telehealth platforms send scales)
• Labs: order metabolic panel, A1C, TSH if not recent (coordinate with PCP or use local lab network)
• Document BMI calculation and qualifying criteria (most states/insurers require BMI ≥30 or ≥27 + comorbidity)

Informed consent (electronic or verbal with documentation):

• Side effects: nausea, vomiting, diarrhea, constipation, risk of pancreatitis, gallstones, thyroid tumors (black box warning on GLP-1s for medullary thyroid cancer in rodents—human risk unclear but document discussion)
• Expectations: this is part of comprehensive care, not a magic pill; need ongoing lifestyle changes
• Mental health monitoring: report any mood changes, suicidal thoughts immediately

Follow-up schedule:

• First month: Weekly or biweekly check-ins during titration (start low—semaglutide begins at 0.25mg weekly—to minimize GI side effects)
• Ongoing: Monthly visits minimum (some states like Florida mandate every 3 months; Virginia initially requires monthly)
• Use telehealth for efficiency: 15-minute med checks to assess weight, side effects, titrate dose

PDMP checks: For controlled substances (phentermine), check your state’s prescription monitoring program before each Rx. Most EMRs integrate this; if yours doesn’t, log in manually and document the check.

Reimbursement: Can You Actually Get Paid for This?

Insurance Coverage is Expanding Fast

Game changer in 2025-2026: Medicare announced it will begin covering FDA-approved weight loss medications (Wegovy, Mounjaro, etc.) after negotiated pricing deals. This follows years of Medicare excluding obesity drugs as ‘cosmetic.’

Medicaid: State-by-state. Some already cover GLP-1s for obesity (with strict prior auth); others will follow Medicare’s lead.

Commercial insurance: Most major plans now cover GLP-1s with prior authorization. Expect payers to require:

• BMI ≥30 or ≥27 + comorbidity (diabetes, hypertension, dyslipidemia)
• Documentation of lifestyle modification attempts (diet, exercise)
• Prescriber attestation that patient is in a comprehensive weight management program

Prior auth tip: Many insurers have templated forms. Answer fully—document the patient’s psychiatric medications that caused weight gain, comorbidities, previous weight loss attempts. This strengthens the case.

Supply limits: Some plans (e.g., BCBS Texas) impose 30-day initial supply limits for GLP-1s to monitor adherence and reduce waste. You’ll write a one-month script, reassess, then continue if tolerated.

Billing Codes for Psychiatrists

E/M codes (99202-99215): Use standard outpatient E/M codes based on visit complexity. A weight management follow-up might be a 99213 (15 min, low complexity) or 99214 (25 min, moderate complexity) depending on how much time you spend counseling on diet, exercise, side effects, adjusting dose, addressing mental health.

Initial psychiatric evaluation (90792): If you’re seeing a new patient and doing both psych eval and initiating weight management, code 90792. Medicare reimburses ~$200 for this.

Obesity counseling codes (G0447): Medicare has specific codes for obesity behavioral counseling (15-min sessions). Psychiatrists can use these if you’re providing nutritional/lifestyle counseling, but most of you will stick with E/M codes since you’re managing meds, not purely counseling.

Telehealth modifiers: Add modifier 95 or place of service POS 02 to indicate telehealth. With payment parity laws in many states (CA, NY, IL, etc.), insurers must reimburse telehealth visits at the same rate as in-person.

MD vs. NP Reimbursement

Psychiatrists (MD/DO): Paid at 100% of physician fee schedule. For a 99214, expect ~$110-130 from Medicare (varies by region); commercial payers often higher.

PMHNPs: Medicare pays 85% of physician rate when billed under NP’s NPI. Some commercial insurers pay 85-100%. Exception: Illinois Medicaid pays NPs 100%, making IL one of the most financially attractive states for NP practice.

Incident-to billing: Some practices try to bill NP visits ‘incident to’ the physician at 100% rates, but this requires the MD to see the patient initially and be on-site for follow-ups—rarely works in pure telehealth models. Stick with billing under the actual rendering provider’s NPI.

Cash Pay Option

Many boutique telehealth weight loss services operate cash-pay (monthly membership $99-199/month plus cost of meds). This avoids insurance billing headaches but limits your market to patients who can afford it. With insurance coverage expanding, expect more patients to prefer going through their plan.

Manufacturer patient assistance: Novo Nordisk and Eli Lilly offer savings cards and patient assistance programs for uninsured/underinsured patients. Familiarize yourself with these to help patients afford meds.

Economics: Is Weight Management Worth Adding to Your Practice?

Let’s talk real numbers.

Patient demand: Obesity affects ~42% of U.S. adults. Among your psychiatric patients, rates are likely higher (medication side effects, depression-obesity cycle). If you see 100 patients, conservatively 30-40 could benefit from weight management.

Appointment volume: Weight management visits are typically shorter than full therapy sessions:

• Initial consult: 30-45 min
• Follow-ups: 15-20 min (med checks, titration, monitoring)

You can stack several weight management follow-ups in an hour via telehealth, making this high-volume, efficient work.

Revenue per patient:

• Insurance reimbursement: ~$75-130 per follow-up visit (depending on code and payer)
• Frequency: Monthly visits minimum = 12 visits/year per patient
• Yearly revenue per patient on insurance: $900-1,560

If you manage 10 weight loss patients, that’s roughly $9,000-15,600/year in additional revenue. Scale to 50 patients, and you’re looking at $45,000-78,000 annually—just for 15-minute monthly check-ins you can do between regular psych appointments.

Cash-pay model: Charge $100-150/month per patient for unlimited messaging + monthly video check-in. 20 cash-pay patients = $24,000-36,000/year.

Compare to DIY marketing costs: If you tried to acquire these patients yourself through Google Ads, SEO, or directories:

• Google Ads for ‘weight loss doctor near me’: $15-40 per click
• Conversion rate: ~5-10% of clicks book (most just browse)
• Real cost per booked patient: $200-400+ when you factor in ad spend, staff time handling leads, no-shows, failed campaigns
• SEO takes 6-12 months of consistent investment ($1,500-3,000/month for content, backlinks, optimization) before you see meaningful patient flow
• Psychology Today/Zocdoc: Monthly fees ($50-200) + per-booking fees ($35-100) + you compete with hundreds of other providers on the same page

On a platform like Klarity: You pay a standard listing fee per new patient appointment (similar to Zocdoc’s model but integrated with telehealth tools). No upfront ad spend. No gambling on whether your SEO will rank. Pre-qualified patients already matched to your specialty and availability. You control your schedule and only pay when you actually see someone.

ROI comparison:

• DIY marketing: Spend $3,000-5,000/month for uncertain results, maybe land 10-15 new patients if lucky (and if your campaign doesn’t flop)
• Platform model: Zero upfront spend. See 10-15 new patients, pay per appointment. Guaranteed ROI because you’re only charged when revenue is generated.

For most providers—especially those starting out or expanding into weight management—removing patient acquisition risk entirely is worth the per-appointment fee. You focus on clinical care; the platform handles marketing, scheduling, credentialing, and telehealth infrastructure.

Compliance Pitfalls (and How to Avoid Them)

Prescribing to unqualified patients: Don’t write for someone with BMI 26 and no comorbidity just because they want to lose 10 lbs for a wedding. Document clear medical necessity (BMI ≥30 or ≥27 + diabetes, hypertension, etc.). State boards will investigate if a pattern emerges.

Skipping follow-ups: Florida mandates every 3 months. Virginia wants monthly initially. Even if your state doesn’t specify, standard of care for GLP-1s (per FDA labeling and clinical guidelines) is regular monitoring for side effects, weight progress, and dose titration. Schedule follow-ups proactively. Missing them for months risks patient harm (undiagnosed pancreatitis, gallstones) and board discipline.

Using compounded semaglutide from sketchy sources: During the 2023-2024 Wegovy shortage, compounding pharmacies proliferated. Some used non-FDA-approved salt forms (semaglutide sodium instead of semaglutide base) or non-pharmaceutical-grade ingredients. Alabama, Florida, and other state boards issued warnings. Only prescribe compounded semaglutide if:

• There’s a genuine shortage (check FDA drug shortage list)
• Pharmacy is a registered 503B outsourcing facility
• They’re using FDA-sanctioned ingredients

Otherwise, stick with FDA-approved products (Wegovy, Saxenda, Mounjaro/Zepbound).

Inadequate telehealth documentation: Mississippi suspended a doctor’s license in 2023 for prescribing Ozempic via instant messaging with no video. Document every telehealth visit thoroughly:

• Modality used (video, audio-only if permitted)
• Patient’s location (confirms you’re licensed in that state)
• Exam findings (even if limited—ask patient to step on scale on camera, describe appearance if assessing for edema or other visual signs)
• Discussion of risks/benefits, patient questions answered

Not checking PDMP for controlled substances: If you prescribe phentermine, check your state’s prescription monitoring program before writing the script. Most states legally require it for Schedule II-IV drugs. Failure to check can result in fines or license discipline.

Operating without required physician oversight (for NPs): If you’re a PMHNP in Texas, Florida, or another restricted state and you prescribe without a valid collaborative agreement, you’re practicing outside your scope. State nursing boards take this seriously. Ensure your agreement is signed, up-to-date, and explicitly covers weight management and controlled substances if applicable.

Training and Competency: How to Actually Get Good at This

You’re a psychiatric prescriber, not an endocrinologist. How do you fill the knowledge gap?

Minimum Recommended Education:

GLP-1 pharmacology deep dive: Understand mechanism (GLP-1 receptor agonism slows gastric emptying, increases satiety, improves glucose metabolism), dosing schedules (semaglutide: 0.25mg→0.5mg→1mg→1.7mg→2.4mg weekly over ~4-5 months), side effect management (anti-nausea meds, slow titration), contraindications (personal/family history of medullary thyroid cancer, MEN2, pregnancy).

Obesity medicine basics: Pathophysiology of obesity (genetics, set point theory, hormonal regulation), lifestyle interventions (behavioral counseling, nutrition basics, exercise recommendations), when to refer to bariatric surgery, managing comorbidities (diabetes, sleep apnea, NAFLD).

CME courses: Look for ACCME-accredited obesity medicine CME. The Obesity Medicine Association offers courses (some free, some paid). American Psychiatric Association has started offering CME on metabolic effects of psych meds—helpful for understanding the psychiatry-obesity overlap.

Obesity Medicine Board Certification (Optional but Powerful):

ABOM (American Board of Obesity Medicine) certification is open to any licensed physician (MD/DO), including psychiatrists. Requirements:

• Complete ~60 hours of obesity-specific CME
• Pass a comprehensive exam covering obesity science, nutrition, pharmacotherapy, bariatrics, behavioral interventions

Why do it?

• Legitimizes your scope of practice (no one can say ‘you’re not qualified’)
• Deepens your clinical knowledge—you’ll learn nuances like when to use phentermine vs. GLP-1, how to manage stalls, combination therapy
• Opens doors to consulting, speaking, or building a subspecialty niche

Timeline: ~6-12 months of study while practicing. Cost: ~$1,500-2,500 (exam fee, prep materials, CME). ROI: Potentially significant if you market yourself as dual-certified psych/obesity specialist.

Collaborative Learning:

Join online communities: Obesity Medicine Association, psychiatric forums discussing GLP-1s, telehealth provider Slack groups. Case discussions help you learn from others’ experience (e.g., ‘patient developed severe nausea at 0.5mg semaglutide—how do you manage?’).

Consult with endocrinology or bariatric colleagues: Especially early on, having a specialist you can ping with questions (or refer complex cases) is invaluable. Many endocrinologists are happy to collaborate—they’re overwhelmed with demand.

Getting Started: Your First 10 Weight Management Patients

Step 1: Assess Your Current Patient Panel

Review your active patients. Flag those who:

• Gained significant weight on your prescribed meds (antipsychotics, mood stabilizers, mirtazapine)
• Have BMI ≥30 (or ≥27 + diabetes/hypertension)
• Express frustration about weight in sessions
• Would benefit from integrated mental health + metabolic care

Bring it up proactively: ‘I’ve noticed your weight has increased since starting quetiapine, and you mentioned feeling self-conscious about it. I’m now offering weight management as part of our treatment. Would you be interested in discussing medication options like GLP-1s?’

Step 2: Set Up Your Workflow

EMR templates: Create a weight management visit template (intake questionnaire covering weight history, diet/exercise, medical contraindications; follow-up template for side effects, weight tracking, dose adjustments).

Consent forms: Electronic consent covering GLP-1 risks (nausea, pancreatitis, thyroid cancer warning, pregnancy contraindication).

Lab orders: Standing orders for CMP, A1C, TSH, lipid panel (coordinate with local labs if patient doesn’t have recent results).

Pharmacy partnerships: If you’re using compounded semaglutide (during shortages or for cost), vet your pharmacy rigorously. Otherwise, send scripts to patient’s preferred retail pharmacy or specialty pharmacy for brand GLP-1s.

Step 3: Master Titration and Troubleshooting

Semaglutide (Wegovy) typical schedule:

• Weeks 1-4: 0.25mg weekly
• Weeks 5-8: 0.5mg weekly
• Weeks 9-12: 1mg weekly
• Weeks 13-16: 1.7mg weekly
• Week 17+: 2.4mg weekly (maintenance)

Common issues:

• Nausea: Start lower, titrate slower, prescribe ondansetron PRN, advise small frequent meals
• Constipation: Increase fiber, hydration, consider MiraLAX
• Plateau after initial loss: Reassure (normal after first 10-15 lbs), reassess diet/exercise, consider dose increase if not at max
• Insurance denies: Help patient appeal (provide letter of medical necessity emphasizing psych med-induced weight gain, failed lifestyle modifications, comorbidities)

Step 4: Document Like a Pro

Every visit note should include:

• Weight and BMI (document trend)
• Medication review (current dose of GLP-1, any psychiatric meds causing weight gain)
• Side effects (ask about GI issues, mood changes, injection site reactions)
• Lifestyle counseling (document that you discussed diet, exercise—even if brief: ‘Reviewed portion control and encouraged 30 min walking 5x/week’)
• Plan (dose adjustment, next follow-up date, labs ordered)

Why this matters: If you’re ever audited or a patient has a bad outcome, your documentation proves you met the standard of care.

Step 5: Join a Platform That Handles Patient Acquisition

Building a weight management practice from scratch via DIY marketing is expensive and slow:

• SEO: 6-12 months, $2,000-4,000/month with no guarantee of ranking
• Google Ads: $3,000-5,000/month ad spend for maybe 10-20 qualified leads (and most won’t convert)
• Directories: Monthly fees, you compete with hundreds of others, unpredictable results

Klarity’s model: You join the network, set your availability, and see pre-qualified patients who are already looking for psychiatric or weight management care via telehealth. You pay a per-appointment fee (like Zocdoc but integrated with full telehealth infrastructure). No upfront marketing cost. No wasted ad spend. You only pay when a patient books and you deliver care.

Why this matters for weight management:

• Patients are matched based on your specialties (psychiatry + weight management)
• Built-in scheduling, billing, telehealth platform (no need to buy Zoom, Doxy, SimplePractice separately)
• Insurance credentialing handled (or cash-pay options if you prefer)
• You control your schedule—see 5 weight management patients a week or 25

Compare ROI:

• DIY: Spend $4,000/month, maybe acquire 10 patients (if lucky), but also waste money on clicks/leads that ghost or no-show
• Klarity: Zero upfront spend, see 10 patients, pay per visit. Guaranteed revenue because you’re only charged when appointments happen.

For most providers, especially those adding a new service line (weight management), removing patient acquisition risk is the smart economic move. Focus your energy on clinical care, not becoming a marketing expert.

FAQs: Weight Loss Prescribing for Psychiatrists and PMHNPs

Can psychiatrists legally prescribe Wegovy or Ozempic for weight loss?

Yes. Psychiatrists (MD/DO) have full prescriptive authority in all 50 states. You can prescribe FDA-approved obesity medications (Wegovy, Saxenda, phentermine, etc.) as long as you’re practicing within your competency. No special certification required, though obesity medicine training

Source:

• https://www.medicaldirectorco.com/collaborative-physician-cost-weight-loss-telehealth/#:~:text=The%20answer%20is%20almost%20always,yes
• https://www.medicaldirectorco.com/collaborative-physician-cost-weight-loss-telehealth/#:~:text=Nurse%20Practitioners%20
• https://journals.lww.com/tnpj/fulltext/2024/01000/36thannualaprnlegislativeupdate__improving.6.aspx#:~:text=The%20Pennsylvania%20BON%20grants%20CRNPs%2C,more%20physicians%20to%20deliver%20healthcare
• https://journals.lww.com/tnpj/fulltext/2024/01000/36thannualaprnlegislativeupdate__improving.6.aspx#:~:text=The%20Illinois%20Department%20of%20Financial,collaborative%20agreement%20following%20a%20TTP
• https://rxagent.co/blog/telehealth-compliance-trap#:~:text=The%20DEA%20gave%20us%20the,evaluation%20at%20the%20federal%20level
• https://rxagent.co/blog/telehealth-compliance-trap#:~:text=Despite%20federal%20DEA%20waivers%20extending,traps%20for%20digital%20health%20providers
• https://rxagent.co/blog/telehealth-compliance-trap#:~:text=1.%20Florida%3A%20The%20%22No,for%20Stimulants
• https://www.mondaq.com/unitedstates/healthcare/1447512/a-changing-regulatory-and-reimbursement-landscape-for-weight-loss-drugs#:~:text=New%20Jersey%20law%20requires%20that,and%20identify%20the%20risks%20associated
• https://drlewis.com/glp-1-medications-psychiatry/#:~:text=You%20know%20these%20drugs,disorders%2C%20and%20possibly%20depression%20itself
• https://drlewis.com/glp-1-mental-health/#:~:text=Now%20let%E2%80%99s%20talk%20about%20potential,where%20things%20get%20really%20interesting